IP Library Granted Patent US 11,779,541
Granted Patent B2
US 11,779,541 · App. 16/364,244 · Granted Oct 10, 2023

Immediate release dosage form

Inventors: Jitendra Krishan Somani (Waterloo, CA); Murali K. Vuppala (Collegeville, PA)
Assignee: Johnson & Johnson Consumer Inc.
A61K9/2009A61K9/2013A61K9/2027A61K9/2054A61K9/2059A61K9/284A61K31/192
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,541
App. No.
16/364,244
Granted
Oct 10, 2023
Kind
B2
Abstract

An improved immediate release solid dosage form of naproxen with a certain particle size distribution for the intragranular portion, and a certain particle size distribution for the carbonate portion that allows naproxen to remain in solution and achieves fast dissolution and fast absorption of naproxen. The invention provides a naproxen dosage form that when administered to a human in a fasted state provides an average blood plasma naproxen concentration of at least 15-20 μg/ml in 10 minutes or less. The invention also provides a naproxen dosage form that when administered to a human in a fed state provides an average blood plasma naproxen concentration of at least 15-20 μg/ml in 50 minutes or less.

Claims (10)

1. A method of administering naproxen which consists of providing to a human in a fasted state an immediate release solid dosage form of naproxen, said solid dosage form providing a blood plasma naproxen concentration of at least 15-20 μg/ml in 10 minutes or less, wherein the solid dosage form comprises an intragranular portion and a carbonate portion, wherein the intragranular portion comprises 220 mg of naproxen sodium, as well as compression filler, binder and disintegrant, wherein the carbonate portion comprises an effective amount of soluble carbonate at a particle size from about 50 microns to 200 microns so as to raise the pH and facilitate dissolution and absorption of the naproxen to begin in the human's stomach, wherein the particle size of the intragranular portion is from about 200 microns to 400 microns, and wherein the solid dosage form does not include any other drug besides naproxen sodium.

2. A method of administering naproxen according to claim 1 wherein the dosage form provides a blood plasma naproxen concentration of at least 15-20 μg/ml in 7-9 minutes.

3. A method of administering naproxen according to claim 1 wherein the particle size of the carbonate is from about 75 microns to 100 microns.

4. A method of administering naproxen according to claim 1 wherein the amount of carbonate in the dosage form is from about 300 mg to 500 mg.

5. A method of administering naproxen according to claim 1 wherein the particle size of the intragranular portion is from about 200 microns to 300 microns.

6. A method of administering naproxen which consists of providing to a human in a fed state an immediate release solid dosage form of naproxen, said solid dosage form providing a blood plasma naproxen concentration of at least 15-20 μg/ml in 50 minutes or less, wherein the solid dosage form comprises an intragranular portion and a carbonate portion, wherein the intragranular portion comprises 220 mg of naproxen sodium, as well as compression filler, binder and disintegrant, wherein the carbonate portion comprises an effective amount of soluble carbonate at a particle size from about 50 microns to 200 microns so as to raise the pH and facilitate dissolution and absorption of the naproxen to begin in the human's stomach, wherein the particle size of the intragranular portion is from about 200 microns to 400 microns, and wherein the solid dosage form does not include any other drug besides naproxen sodium.

7. A method of administering naproxen according to claim 6 wherein the dosage form provides a blood plasma naproxen concentration of at least 15-20 μg/ml in 25 minutes or less.

8. A method of administering naproxen according to claim 6 , wherein the particle size of the carbonate is from about 75 microns to 100 microns.

9. A method of administering naproxen according to claim 6 , wherein the amount of carbonate in the dosage form is from about 300 mg to 500 mg.

10. A method of administering naproxen according to claim 6 , wherein the particle size of the intragranular portion is from about 200 to 300 microns.

Assignments (7)
CHANGE OF NAME Recorded Oct 28, 2024
From: JOHNSON & JOHNSON CONSUMER INC.
To: KENVUE BRANDS LLC
Reel/Frame 069267/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0372 →
CERTIFICATE OF CONVERSION Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0521 →
MERGER Recorded Jan 27, 2022
From: JOHNSON & JOHNSON CONSUMER INC.
To: CHENANGO ZERO LLC
Reel/Frame 059618/0521 →
MERGER Recorded Jan 27, 2022
From: CHENANGO ZERO LLC
To: CHENANGO TWO LLC
Reel/Frame 058888/0133 →
MERGER AND CHANGE OF NAME Recorded Jan 27, 2022
From: CHENANGO TWO LLC; CURRAHEE HOLDING COMPANY INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 058888/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: SOMANI, JITENDRA KRISHAN; VUPPALA, MURALI K.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 048934/0543 →
Continuity (1)
Related Publication 20200306192A1 · Oct 1, 2020